Three months af­ter big re­or­ga­ni­za­tion, an­ti­body mak­er Atre­ca is back with an­oth­er round of lay­offs

Atre­ca is let­ting an­oth­er 40% of its staff go in a move ex­pect­ed to keep it­self afloat through the first quar­ter of 2024 as it ex­plores strate­gic al­ter­na­tives.

The biotech is fo­cused on ad­vanc­ing APN-497444, an an­ti­body-drug con­ju­gate tar­get­ing a tu­mor-spe­cif­ic gly­can, through pre­clin­i­cal test­ing. Its fund­ing needs for that pro­gram and oth­er fol­low-up AD­Cs, cou­pled with cur­rent fi­nan­cial mar­ket con­di­tions, led to the de­ci­sion, Atre­ca CEO John Or­win said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER